Echo is excited to offer continued support to Octave Bioscience in its $32 million Series B financing round. This financing will advance the company’s care management platform for multiple sclerosis (MS) and other neurodegenerative diseases as it begins to serve neurologists, MS patients and health plans.

Learn more in the full release: Octave Bioscience Secures $32 Million Series B Financing.